Berberine attenuates liver fibrosis via inhibition of Ang-2 through the toll-like receptor 4-mediated signaling pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115673 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Hong Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Traditional Chinese Medicine Clinical Research Base and Drug Research Center, the Affiliated Traditional Chinese Medicine Hospital, Southwes…. Hauptthemen laut MEDLINE: Berberine, Toll-Like Receptor 4, Angiopoietin-2, Liver Cirrhosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Health Commission of Sichuan Province, Sichuan Provincial Science and Technology Support Program.
Abstract (Originalsprache)
Liver fibrosis, a key pathological feature in chronic liver injury, accelerates chronic liver disease (CLD) progression to cirrhosis. Fibrogenesis relies on angiogenesis balance, namely, physiological angiogenesis mitigates liver injury while pathological angiogenesis drives excessive collagen deposition and fibrotic progression. Therefore, targeting key regulators governing the transition from physiological to pathological angiogenesis is critical for treating liver fibrosis. In this study, two murine models of chronic liver injury were established: a carbon tetrachloride (CCl4)-induced fibrosis model and a non-alcoholic steatohepatitis (NASH) model. Both models exhibited elevated angiopoietin-2 (Ang-2) levels, concomitant with marked activation of endothelial-mesenchymal transition (EMT). Furthermore, to delineate the angiogenic role of Ang-2, liver-specific Ang-2 knockdown (Ang-2-/-) mice were generated. Ang-2 gene deletion attenuated EMT activation, demonstrating its critical contribution to fibrogenesis. Finally, berberine (BBR), a hepatoprotective alkaloid derived from Rhizoma Coptidis, attenuated liver fibrosis by suppressing Ang-2 expression through TLR4 signaling inhibition. In summary, this study highlights the therapeutic potential of BBR for its clinical application by identifing Ang-2 as a novel regulator of endothelial-cell (EC) proliferation in liver fibrosis and demonstrates that BBR inhibits fibrogenesis via TLR4-mediated Ang-2 suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Traditional Chinese Medicine Clinical Research Base and Drug Research Center, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China; Institute of Integrated Ch…
- Sino-Portugal TCM International Cooperation Center, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
- The Czech Center for Traditional Chinese Medicine, Jeremenkova 1211/40, Olomouc 77900, Czechia. Electronic address: roman@czcn.eu.
Förderung
- Health Commission of Sichuan Province
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Wang, H., Zhou, Y., He, W., Zhao, F., Spáčil, R., Ren, W., & Ma, Y. (2025). Berberine attenuates liver fibrosis via inhibition of Ang-2 through the toll-like receptor 4-mediated signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115673
Vancouver
Wang H, Zhou Y, He W, Zhao F, Spáčil R, Ren W, et al. Berberine attenuates liver fibrosis via inhibition of Ang-2 through the toll-like receptor 4-mediated signaling pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115673
BibTeX
@article{Wang2025,
author = {Wang, Hong and Zhou, Yanan and He, Wenlu and Zhao, Fulan and Spáčil, Roman and Ren, Wei and Ma, Yining},
title = {Berberine attenuates liver fibrosis via inhibition of Ang-2 through the toll-like receptor 4-mediated signaling pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115673}
}
EUVIMED